Stocks
Axsome Therapeutics (AXSM) EBITDA US GAAP (year values) |
|||||||||
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | LTM ? | CAGR 5 years ? | |||
| EBITDA, bln rub | ? | -124.6 | -175.4 | -225.0 | -272.6 | -168.1 | -172.7 | ||
| Changes by years, y/y, % | +24% | +41% | +28% | +21% | -38% | +10.9% | |||
Axsome Therapeutics. EBITDA US GAAP, bln rub
Axsome Therapeutics. EBITDA US GAAP, changes, %
Axsome Therapeutics. EBITDA US GAAP, sum by quarters, bln rub
Axsome Therapeutics (AXSM) EBITDA US GAAP (quarter values) |
||||||||
| FY2025Q1 | FY2025Q2 | FY2025Q3 | FY2025Q4 | FY2026Q1 | LTM ? | |||
| EBITDA, bln rub | ? | -54.8 | -42.6 | -44.4 | -24.7 | -61.1 | -172.7 | |
| Changes by years, y/y, % | -16% | -44% | -27% | -65% | +11% | |||
| Changes by quarters, q/q, % | -22% | -22% | +4% | -44% | +147% | |||
